Mandy J McGeachy, PhD
Campus: BST South, S719, 3500 Terrace Street
Pittsburgh, PA 15261
- BSc, University of Glasgow, Scotland, UK, 2001
- PhD, University of Edinburgh, Scotland, UK, 2005
- Postdoc, Schering-Plough Biopharma/DNAX, 2009
- Assistant Professor
- Assistant Professor, Division of Rheumatology & Clinical Immunology, Department of Medicine
The McGeachy lab studies mechanisms of activation and regulation of Th17 cells in autoimmune inflammation. In the past decade, Th17 cells have moved to the forefront as drivers of autoimmune inflammation, and therapies to target Th17-associated pathways are making remarkable progress in clinic. Since these cells were only defined as a distinct subset a decade ago, there is still much to know about their functional regulation. Using models of multiple sclerosis (EAE), we have identified novel integrins that are expressed by Th17 cells and important for their inflammatory function. Ongoing NIH-funded mechanistic studies are investigating the mechanisms through which integrins regulate Th17 inflammation in different tissues. We are also studying inflammatory T cells in humans with rheumatoid arthritis and thyroiditis-associated eye disease (TED), analyzing peripheral blood and more recently RA joint synovial tissue. Biologic therapy in patients offers the opportunity to determine changes in T cells that are related to blockade of specific immune pathways, and we are collaborating with rheumatologists to analyze changes in T cell populations that correspond to therapy.
Du F, Garg AV, Kosar K, Majumder S, Kugler DG, Mir GH, Maggio M, Henkel M, Lacy-Hulbert A, McGeachy MJ “Inflammatory Th17 Cells Express Integrin αvβ3 for Pathogenic Function” Cell Reports, 2016
Conti HR, Peterson AC, Brane L, Huppler AR, Hernández-Santos N, Whibley N, Garg AV, Simpson-Abelson MR, Gibson GA, Mamo AJ, Osborne LC, Bishu S, Ghilardi N, Siebenlist U, Watkins SC, Artis D, McGeachy MJ, Gaffen SL “Oral-resident natural Th17 cells and gd T cell control opportunistic Candida albicans infections” J Exp Med 2014
Bishu S, Su EW, Wilkerson ER, Reckley KA, Jones, DM, McGeachy MJ, Gaffen SL, Levesque MC “Rheumatoid Arthritis Patients Exhibit Impaired Candida-albican specific Th17 responses” Arthritis Research & Therapy, 2014
Haines CJ, Chen Y, Blumenschein WB, Jain R, Chang C, Joyce-Shaikh B, Porth K, Leech MD, Boniface K, Mattson J, Basham B, Anderton SM, McClanahan T, Sadekova S, Cua DJ, McGeachy MJ “Autoimmune Th17 Memory Cell Function and Expansion are Dependent on IL-23” Cell Reports, 2013
McGeachy MJ “Th17 Memory Cells: Live Long and Proliferate” J Leuokocyte Biology 2013
Chen Y, Hochweller K, Haines C, Blumenschein WB, McClanahan T, Hammerling G, Cua DJ, McGeachy MJ. Foxp3+ Regulatory T cells Promote Th17 Development in vivo. Immunity 2011.
McGeachy MJ. GM-CSF: the secret weapon in the T(H)17 arsenal. Nature Immunology 2011.
McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein W, McClanahan T, O'Shea JJ, Cua DJ. Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo. Nature Immunology, 2009.
McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ. Transforming growth factor and interleukin 6 drive T cell production of interleukins 17 and 10 and restrain TH-17–mediated pathology. Nature Immunology, 2007.